Direct-to-consumer DNA testing firm 23andMe Holding Co. said on Friday it would buy privately held company Lemonaid Health Inc. for $400 million in a cash-and-stock deal, as it looks to expand into telemedicine.
Lemonaid Health offers patients direct online access for a number of common conditions, from consultation through treatment. It also offers free and fast delivery of prescription medications.
“By starting with genetics as the foundation, we will give patients and healthcare providers better information about health risks and treatment,” 23andMe Chief Executive Officer Anne Wojcicki said in a statement.
Sunnyvale, California-based 23andMe is known for its genetic ancestry tests but also aims to develop treatments for diseases such as cancer and respiratory disorders.
The company said it would pay 25% of the total deal value in cash and the rest in shares.
The deal is expected to close by the end of 2021.
23andMe went public in February through a blank-check firm, backed by Virgin Group founder Sir Richard Branson, in a deal that valued the merged entity at $3.5 billion.
(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)
Topics Mergers & Acquisitions
Was this article valuable?
Here are more articles you may enjoy.
Acrisure to Cut 2,250 Employees, Citing Advances in Technology and AI 
First Brands Hit by $286 Million Claim for Alleged Tariffs Fraud 
Florida Court Says 2020 Law Gives ‘Very Broad’ Liability Immunity to Rideshare Firms 
Viewpoint: The AI Boom – When Risk Stops Being Rare, Insurance Must Evolve 
